{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:58:50Z","timestamp":1790384330364,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:00:00Z","timestamp":1782518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s40120-026-00984-2","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T04:53:43Z","timestamp":1782536023000},"page":"2761-2774","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Utility of Multi-Analyte Protein Assay to Distinguish Multiple Sclerosis Clinical Relapse from Pseudoexacerbation"],"prefix":"10.1007","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6499-1523","authenticated-orcid":false,"given":"Darin T.","family":"Okuda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatum M.","family":"Moog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan C.","family":"McCreary","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabella J.","family":"Huddleston","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Crystal M.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katy W.","family":"Burgess","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose R.","family":"Santoyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter V.","family":"Sguigna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olaf","family":"St\u00fcve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diem H.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,27]]},"reference":[{"issue":"11","key":"984_CR1","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1016\/S1474-4422(23)00281-8","volume":"22","author":"C Lebrun-Frenay","year":"2023","unstructured":"Lebrun-Frenay C, Kantarci O, Siva A, Azevedo CJ, Makhani N, Pelletier D, et al. Radiologically isolated syndrome. Lancet Neurol. 2023;22(11):1075\u201386.","journal-title":"Lancet Neurol"},{"issue":"7","key":"984_CR2","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1001\/jamaneurol.2023.1135","volume":"80","author":"M Hittle","year":"2023","unstructured":"Hittle M, Culpepper WJ, Langer-Gould A, Marrie RA, Cutter GR, Kaye WE, et al. Population-based estimates for the prevalence of multiple sclerosis in the United States by Race, Ethnicity, Age, Sex, and Geographic Region. JAMA Neurol. 2023;80(7):693\u2013701.","journal-title":"JAMA Neurol"},{"key":"984_CR3","doi-asserted-by":"crossref","unstructured":"Interferon beta-1b is effective in relapsing-remitting multiple sclerosis. I. Clinical results of a multicenter, randomized, double-blind, placebo-controlled trial. The IFNB Multiple Sclerosis Study Group. Neurology. 1993;43(4):655\u201361.","DOI":"10.1212\/WNL.43.4.655"},{"issue":"7","key":"984_CR4","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1212\/WNL.45.7.1268","volume":"45","author":"KP Johnson","year":"1995","unstructured":"Johnson KP, Brooks BR, Cohen JA, Ford CC, Goldstein J, Lisak RP, et al. Copolymer 1 reduces relapse rate and improves disability in relapsing\u2010remitting multiple sclerosis: Results of a phase III multicenter, double\u2010blind, placebo\u2010controlled trial. Neurology. 1995;45(7):1268\u201376.","journal-title":"Neurology"},{"issue":"9","key":"984_CR5","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1056\/NEJMoa044397","volume":"354","author":"CH Polman","year":"2006","unstructured":"Polman CH, O\u2019Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354(9):899\u2013910.","journal-title":"N Engl J Med"},{"issue":"5","key":"984_CR6","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1056\/NEJMoa0909494","volume":"362","author":"L Kappos","year":"2010","unstructured":"Kappos L, Radue EW, O\u2019Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387\u2013401.","journal-title":"N Engl J Med"},{"issue":"3","key":"984_CR7","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1016\/S1474-4422(13)70308-9","volume":"13","author":"C Confavreux","year":"2014","unstructured":"Confavreux C, O\u2019Connor P, Comi G, Freedman MS, Miller AE, Olsson TP, et al. Oral teriflunomide for patients with relapsing multiple sclerosis (TOWER): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(3):247\u201356.","journal-title":"Lancet Neurol"},{"issue":"12","key":"984_CR8","doi-asserted-by":"publisher","first-page":"1098","DOI":"10.1056\/NEJMoa1114287","volume":"367","author":"R Gold","year":"2012","unstructured":"Gold R, Kappos L, Arnold DL, Bar-Or A, Giovannoni G, Selmaj K, et al. Placebo-controlled phase 3 study of oral BG-12 for relapsing multiple sclerosis. N Engl J Med. 2012;367(12):1098\u2013107.","journal-title":"N Engl J Med"},{"issue":"9856","key":"984_CR9","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1016\/S0140-6736(12)61769-3","volume":"380","author":"JA Cohen","year":"2012","unstructured":"Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung HP, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380(9856):1819\u201328.","journal-title":"Lancet"},{"issue":"3","key":"984_CR10","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1056\/NEJMoa1601277","volume":"376","author":"SL Hauser","year":"2017","unstructured":"Hauser SL, Bar-Or A, Comi G, Giovannoni G, Hartung HP, Hemmer B, et al. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis. N Engl J Med. 2017;376(3):221\u201334.","journal-title":"N Engl J Med"},{"issue":"3","key":"984_CR11","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/S1474-4422(14)70005-5","volume":"13","author":"TP Leist","year":"2014","unstructured":"Leist TP, Comi G, Cree BA, Coyle PK, Freedman MS, Hartung HP, et al. Effect of oral cladribine on time to conversion to clinically definite multiple sclerosis in patients with a first demyelinating event (ORACLE MS): a phase 3 randomised trial. Lancet Neurol. 2014;13(3):257\u201367.","journal-title":"Lancet Neurol"},{"issue":"7","key":"984_CR12","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1038\/sc.2014.238","volume":"53","author":"LH Hua","year":"2015","unstructured":"Hua LH, Donlon SL, Sobhanian MJ, Portner SM, Okuda DT. Thoracic spinal cord lesions are influenced by the degree of cervical spine involvement in multiple sclerosis. Spinal Cord. 2015;53(7):520\u20135.","journal-title":"Spinal Cord"},{"issue":"6","key":"984_CR13","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1002\/ana.410320609","volume":"32","author":"HF McFarland","year":"1992","unstructured":"McFarland HF, Frank JA, Albert PS, Smith ME, Martin R, Harris JO, et al. Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol. 1992;32(6):758\u201366.","journal-title":"Ann Neurol"},{"issue":"1","key":"984_CR14","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1001\/jamaneurol.2019.3238","volume":"77","author":"K Bjornevik","year":"2020","unstructured":"Bjornevik K, Munger KL, Cortese M, Barro C, Healy BC, Niebuhr DW, et al. Serum neurofilament light chain levels in patients with presymptomatic multiple sclerosis. JAMA Neurol. 2020;77(1):58\u201364.","journal-title":"JAMA Neurol"},{"issue":"6","key":"984_CR15","doi-asserted-by":"publisher","first-page":"945","DOI":"10.1002\/acn3.51060","volume":"7","author":"M Rosso","year":"2020","unstructured":"Rosso M, Gonzalez CT, Healy BC, Saxena S, Paul A, Bjornevik K, et al. Temporal association of sNfL and gad-enhancing lesions in multiple sclerosis. Ann Clin Transl Neurol. 2020;7(6):945\u201355.","journal-title":"Ann Clin Transl Neurol"},{"issue":"1","key":"984_CR16","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1007\/s40120-022-00427-8","volume":"12","author":"A Bar-Or","year":"2023","unstructured":"Bar-Or A, Montalban X, Hu X, Kropshofer H, Kukkaro P, Coello N, et al. Serum neurofilament light trajectories and their relation to subclinical radiological disease activity in relapsing multiple sclerosis patients in the APLIOS trial. Neurol Ther. 2023;12(1):303\u201317.","journal-title":"Neurol Ther"},{"key":"984_CR17","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp-2022-329020","author":"M Comabella","year":"2022","unstructured":"Comabella M, Sastre-Garriga J, Carbonell-Mirabent P, Fissolo N, Tur C, Malhotra S, et al. Serum neurofilament light chain levels predict long-term disability progression in patients with progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2022. https:\/\/doi.org\/10.1136\/jnnp-2022-329020.","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"984_CR18","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1001\/jamaneurol.2023.0010","volume":"80","author":"E Monreal","year":"2023","unstructured":"Monreal E, Fernandez-Velasco JI, Garcia-Sanchez MI, Sainz de la Maza S, Llufriu S, Alvarez-Lafuente R, et al. Association of serum neurofilament light chain levels at disease onset with disability worsening in patients with a first demyelinating multiple sclerosis event not treated with high-efficacy drugs. JAMA Neurol. 2023;80(4):397\u2013403.","journal-title":"JAMA Neurol"},{"issue":"2","key":"984_CR19","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ, Banwell BL, Barkhof F, Carroll WM, Coetzee T, Comi G, et al. Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol. 2018;17(2):162\u201373.","journal-title":"Lancet Neurol"},{"issue":"3","key":"984_CR20","doi-asserted-by":"publisher","DOI":"10.1002\/prca.202200018","volume":"17","author":"F Qureshi","year":"2023","unstructured":"Qureshi F, Hu W, Loh L, Patel H, DeGuzman M, Becich M, et al. Analytical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis. Proteomics Clin Appl. 2023;17(3):e2200018.","journal-title":"Proteomics Clin Appl"},{"key":"984_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109688","volume":"253","author":"T Chitnis","year":"2023","unstructured":"Chitnis T, Foley J, Ionete C, El Ayoubi NK, Saxena S, Gaitan-Walsh P, et al. Clinical validation of a multi-protein, serum-based assay for disease activity assessments in multiple sclerosis. Clin Immunol. 2023;253:109688.","journal-title":"Clin Immunol"},{"issue":"9","key":"984_CR22","doi-asserted-by":"publisher","first-page":"792","DOI":"10.1016\/S1474-4422(22)00218-6","volume":"21","author":"I Helmrich","year":"2022","unstructured":"Helmrich I, Czeiter E, Amrein K, Buki A, Lingsma HF, Menon DK, et al. Incremental prognostic value of acute serum biomarkers for functional outcome after traumatic brain injury (CENTER-TBI): an observational cohort study. Lancet Neurol. 2022;21(9):792\u2013802.","journal-title":"Lancet Neurol"},{"key":"984_CR23","doi-asserted-by":"publisher","DOI":"10.3390\/ijms252212379","author":"R Arya","year":"2024","unstructured":"Arya R, Haque A, Shakya H, Billah MM, Parvin A, Rahman MM, et al. Parkinson\u2019s disease: biomarkers for diagnosis and disease progression. Int J Mol Sci. 2024. https:\/\/doi.org\/10.3390\/ijms252212379.","journal-title":"Int J Mol Sci"},{"issue":"11","key":"984_CR24","doi-asserted-by":"publisher","DOI":"10.1111\/cns.70060","volume":"30","author":"Y Dong","year":"2024","unstructured":"Dong Y, Song X, Wang X, Wang S, He Z. The early diagnosis of Alzheimer\u2019s disease: Blood-based panel biomarker discovery by proteomics and metabolomics. CNS Neurosci Ther. 2024;30(11):e70060.","journal-title":"CNS Neurosci Ther"},{"key":"984_CR25","doi-asserted-by":"publisher","DOI":"10.1177\/13524585261423016","author":"A Gavoille","year":"2026","unstructured":"Gavoille A, Vukusic S, Laplaud DA. Do MRI-negative relapses really exist? - Yes. Mult Scler. 2026. https:\/\/doi.org\/10.1177\/13524585261423016.","journal-title":"Mult Scler"},{"issue":"8","key":"984_CR26","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.1007\/s00415-016-8183-3","volume":"263","author":"PJ Jongen","year":"2016","unstructured":"Jongen PJ, Stavrakaki I, Voet B, Hoogervorst E, van Munster E, Linssen WH, et al. Patient-reported adverse effects of high-dose intravenous methylprednisolone treatment: a prospective web-based multi-center study in multiple sclerosis patients with a relapse. J Neurol. 2016;263(8):1641\u201351.","journal-title":"J Neurol"},{"issue":"6","key":"984_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.968","volume":"8","author":"V Nociti","year":"2018","unstructured":"Nociti V, Biolato M, De Fino C, Bianco A, Losavio FA, Lucchini M, et al. Liver injury after pulsed methylprednisolone therapy in multiple sclerosis patients. Brain Behav. 2018;8(6):e00968.","journal-title":"Brain Behav"},{"issue":"9","key":"984_CR28","doi-asserted-by":"publisher","first-page":"1506","DOI":"10.1016\/j.arth.2015.03.036","volume":"30","author":"MA Mont","year":"2015","unstructured":"Mont MA, Pivec R, Banerjee S, Issa K, Elmallah RK, Jones LC. High-dose corticosteroid use and risk of hip osteonecrosis: meta-analysis and systematic literature review. J Arthroplasty. 2015;30(9):1506-12 e5.","journal-title":"J Arthroplasty"},{"issue":"6","key":"984_CR29","doi-asserted-by":"publisher","first-page":"e1442","DOI":"10.1210\/clinem\/dgad701","volume":"109","author":"A Koning","year":"2024","unstructured":"Koning A, van der Meulen M, Schaap D, Satoer DD, Vinkers CH, van Rossum EFC, et al. Neuropsychiatric adverse effects of synthetic glucocorticoids: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2024;109(6):e1442\u201351.","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"984_CR30","doi-asserted-by":"publisher","first-page":"e59","DOI":"10.1016\/j.clinthera.2023.11.013","volume":"46","author":"V Limbachia","year":"2024","unstructured":"Limbachia V, Nunney I, Page DJ, Barton HA, Patel LK, Thomason GN, et al. The effect of different types of oral or intravenous corticosteroids on capillary blood glucose levels in hospitalized inpatients with and without diabetes. Clin Ther. 2024;46(2):e59\u201363.","journal-title":"Clin Ther"},{"issue":"10","key":"984_CR31","doi-asserted-by":"publisher","first-page":"3897","DOI":"10.1007\/s00204-025-04124-x","volume":"99","author":"JL Domingo","year":"2025","unstructured":"Domingo JL, Semelka RC. Gadolinium toxicity: mechanisms, clinical manifestations, and nanoparticle role. Arch Toxicol. 2025;99(10):3897\u2013916.","journal-title":"Arch Toxicol"},{"key":"984_CR32","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3389\/fimmu.2017.00529","volume":"8","author":"P Peschl","year":"2017","unstructured":"Peschl P, Bradl M, Hoftberger R, Berger T, Reindl M. Myelin oligodendrocyte glycoprotein: deciphering a target in inflammatory demyelinating diseases. Front Immunol. 2017;8:529.","journal-title":"Front Immunol"},{"issue":"3","key":"984_CR33","doi-asserted-by":"publisher","first-page":"246","DOI":"10.1016\/S1474-4422(22)00009-6","volume":"21","author":"P Benkert","year":"2022","unstructured":"Benkert P, Meier S, Schaedelin S, Manouchehrinia A, Yaldizli O, Maceski A, et al. Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study. Lancet Neurol. 2022;21(3):246\u201357.","journal-title":"Lancet Neurol"},{"issue":"12","key":"984_CR34","doi-asserted-by":"publisher","first-page":"1550","DOI":"10.1177\/1352458515623365","volume":"22","author":"J Kuhle","year":"2016","unstructured":"Kuhle J, Barro C, Disanto G, Mathias A, Soneson C, Bonnier G, et al. Serum neurofilament light chain in early relapsing remitting MS is increased and correlates with CSF levels and with MRI measures of disease severity. Mult Scler. 2016;22(12):1550\u20139.","journal-title":"Mult Scler"},{"issue":"1","key":"984_CR35","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1038\/s41467-018-03323-8","volume":"9","author":"M Vigolo","year":"2018","unstructured":"Vigolo M, Chambers MG, Willen L, Chevalley D, Maskos K, Lammens A, et al. A loop region of BAFF controls B cell survival and regulates recognition by different inhibitors. Nat Commun. 2018;9(1):1199.","journal-title":"Nat Commun"},{"key":"984_CR36","doi-asserted-by":"publisher","DOI":"10.3390\/biology12040587","author":"MA Zingaropoli","year":"2023","unstructured":"Zingaropoli MA, Pasculli P, Tartaglia M, Dominelli F, Ciccone F, Taglietti A, et al. Evaluation of BAFF, APRIL and CD40L in ocrelizumab-treated pwMS and infectious risk. Biology (Basel). 2023. https:\/\/doi.org\/10.3390\/biology12040587.","journal-title":"Biology (Basel)"},{"key":"984_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.clim.2023.109870","volume":"258","author":"K Asplund Hogelin","year":"2024","unstructured":"Asplund Hogelin K, Isac B, Khademi M, Al NF. B cell activating factor levels are linked to distinct B cell markers in multiple sclerosis and following B cell depletion and repopulation. Clin Immunol. 2024;258:109870.","journal-title":"Clin Immunol"},{"issue":"3","key":"984_CR38","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1007\/s00125-022-05846-8","volume":"66","author":"H Maalmi","year":"2023","unstructured":"Maalmi H, Strom A, Petrera A, Hauck SM, Strassburger K, Kuss O, et al. Serum neurofilament light chain: a novel biomarker for early diabetic sensorimotor polyneuropathy. Diabetologia. 2023;66(3):579\u201389.","journal-title":"Diabetologia"},{"issue":"6","key":"984_CR39","doi-asserted-by":"publisher","first-page":"e518","DOI":"10.1212\/WNL.0000000000004932","volume":"90","author":"A Sandelius","year":"2018","unstructured":"Sandelius A, Zetterberg H, Blennow K, Adiutori R, Malaspina A, Laura M, et al. Plasma neurofilament light chain concentration in the inherited peripheral neuropathies. Neurology. 2018;90(6):e518\u201324.","journal-title":"Neurology"},{"issue":"1","key":"984_CR40","doi-asserted-by":"publisher","first-page":"20350","DOI":"10.1038\/s41598-020-76990-7","volume":"10","author":"S Akamine","year":"2020","unstructured":"Akamine S, Marutani N, Kanayama D, Gotoh S, Maruyama R, Yanagida K, et al. Renal function is associated with blood neurofilament light chain level in older adults. Sci Rep. 2020;10(1):20350.","journal-title":"Sci Rep"},{"issue":"4","key":"984_CR41","doi-asserted-by":"publisher","first-page":"688","DOI":"10.1002\/ana.26446","volume":"92","author":"KC Fitzgerald","year":"2022","unstructured":"Fitzgerald KC, Sotirchos ES, Smith MD, Lord HN, DuVal A, Mowry EM, et al. Contributors to serum NfL levels in people without neurologic disease. Ann Neurol. 2022;92(4):688\u201398.","journal-title":"Ann Neurol"}],"updated-by":[{"DOI":"10.1007\/s40120-026-01005-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T00:00:00Z","timestamp":1786665600000}}],"container-title":["Neurology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00984-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40120-026-00984-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40120-026-00984-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:03:17Z","timestamp":1790380997000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40120-026-00984-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,27]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["984"],"URL":"https:\/\/doi.org\/10.1007\/s40120-026-00984-2","relation":{},"ISSN":["2193-8253","2193-6536"],"issn-type":[{"value":"2193-8253","type":"print"},{"value":"2193-6536","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,27]]},"assertion":[{"value":"11 May 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to correct the sentence starting \"Figure 2 illustrates the...\" and to correct the Tables 4 and 5.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40120-026-01005-y","URL":"https:\/\/doi.org\/10.1007\/s40120-026-01005-y","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Darin T. Okuda received personal compensation for consulting and advisory services from Amgen, Biogen Inc., Cortechs.ai, EMD Serono, Genentech, Genzyme\/Sanofi, Immunic Therapeutics, Moderna, Octave Bioscience, Pfizer, and Zenas BioPharma along with research support from Alexion and Novartis, has issued national and international patents along with pending patents related to other developed technologies, and\u00a0received royalties for intellectual property licensed by The Board of Regents of The University of Texas System. Crystal M. Wright received personal compensation from EMD Serono, Genentech, and TG Therapeutics. Katy W. Burgess received personal compensation from EMD Serono and Sanofi. Peter V. Sguigna received personal compensation for consulting services from Genentech, EMD Serono, Horizon Therapeutics, Amgen, and Bristol Myers Squibb, and has received research support from Clene Nanomedicine, Genentech, Novartis, and Zenas Biopharma. Olaf St\u00fcve serves on the editorial boards of Therapeutic Advances in Neurological Disorders, Expert Review of Clinical Immunology, and he is a section editor for Current Treatment Options in Neurology, has served on data monitoring committees for Genentech-Roche, and Novartis without monetary compensation, has advised Cellarity, Lilly, Octave Bioscience, and Zenas BioPharma, receives grant support from EMD Serono. Tatum M. Moog, Morgan C. McCreary, Isabella J. Huddleston, Jose R. Santoyo, and Diem H. Tran report no disclosures.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by The University of Texas Southwestern Medical Center Institutional Review Board (STU-072016-012) and has, therefore, been performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki and later amendments. A waiver for consent was granted based on the retrospective study design.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}